Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
ImmunoCellular Therapeutics Ltd logo — Pioneering immune-based therapies to harness the body's defe...

ImmunoCellular Therapeutics Ltd

Pioneering immune-based therapies to harness the body's defenses against cancer through advanced immunotherapy development.

Founded 2006 United States Calabasas, United States 11 employees Grant Total: $32.47M Biotechnology, Health Care

General Information

Company Name ImmunoCellular Therapeutics Ltd
Founded Year 2006
Location United States Calabasas, United States
Employees 11
Industries Biotechnology, Health Care
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with ImmunoCellular Therapeutics Ltd. To contact ImmunoCellular Therapeutics Ltd, visit imuc.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does ImmunoCellular Therapeutics Ltd compare?

A PDF of ImmunoCellular Therapeutics Ltd and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting ImmunoCellular Therapeutics Ltd soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About ImmunoCellular Therapeutics Ltd

ImmunoCellular Therapeutics is a biotechnology firm pioneering immune-based therapies to harness the body's defenses against cancer through advanced immunotherapy development. Founded in 2006, the company focuses on creating immune-based treatments for cancers. Its flagship product, ICT-107, is a dendritic cell (DC) immunotherapy designed to treat newly diagnosed glioblastoma multiforme (GBM), a highly aggressive brain cancer. This approach involves stimulating a patient's immune system to target tumor antigens, which are molecular signals used by the immune system to identify foreign bodies. In September 2015, ImmunoCellular Therapeutics secured a significant $19.90M grant investment from the California Institute for Regenerative Medicine. This funding showcased confidence in the potential of the company's immunotherapy technology. ImmunoCellular Therapeutics operates in the biotechnology and healthcare sectors, positioning itself at the intersection of innovative medical advancements and addressing critical oncological needs. Their groundbreaking approach to immunotherapy development holds promise for revolutionizing cancer treatment and making significant strides in improving patient outcomes.

Business keywords: ImmunoCellular Therapeutics, immune-based therapies, immunotherapy development, cancer treatment, clinical-stage, ICT-107, dendritic cell immunotherapy, glioblastoma multiforme, brain cancer, immune system stimulation, tumor antigens, immune response, cancer immunotherapy, patient-specific treatment

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $19.90M 1
California Institute for Regenerative Medicine
24 Sep 2015
Venture Round $8.09M 1
Asset Management Ventures
Asset Management Ventures
11 Mar 2011
Venture Round $2.74M -
02 Jun 2010
Venture Round $1.74M -
12 Apr 2010

ImmunoCellular Therapeutics Ltd Alternatives & Competitors

View All Alternatives
ImmunoCellular Therapeutics Ltd vs
Genenta Science (Nasdaq: GNTA)
Genenta Science (Nasdaq: GNTA) Italy

Genenta is a clinical stage immuno-oncology company

Post-IPO Secondary
25 employees
Biotechnology, Health Care
ImmunoCellular Therapeutics Ltd vs
Prescient Therapeutics
Prescient Therapeutics Australia

A clinical stage oncology company developing personalised medicine approaches to cancer; cellular &...

Post-IPO Equity
14 employees
Biopharma, Biotechnology
ImmunoCellular Therapeutics Ltd vs
TransCode Therapeutics, Inc.
TransCode Therapeutics, Inc. United States

Delivering a cancer-free future

Post-IPO Equity
11 employees
Biotechnology, Health Care
Also compare with: ImmunoCellular Therapeutics Ltd vs Enterome Enterome View all alternatives

FAQ About ImmunoCellular Therapeutics Ltd

Pioneering immune-based therapies to harness the body's defenses against cancer through advanced immunotherapy development.
ImmunoCellular Therapeutics Ltd was founded in 2006.
ImmunoCellular Therapeutics Ltd is headquartered in Calabasas, United States.
ImmunoCellular Therapeutics Ltd operates in Biotechnology and Health Care. Its work centres on ImmunoCellular Therapeutics, immune-based therapies, immunotherapy development and cancer treatment.
ImmunoCellular Therapeutics Ltd has approximately 11 employees.
ImmunoCellular Therapeutics Ltd has completed 4 funding rounds, raising a total of $32.47M. The latest funding stage is Grant.
Top alternatives and competitors to ImmunoCellular Therapeutics Ltd include Genenta Science (Nasdaq: GNTA), Prescient Therapeutics, TransCode Therapeutics, Inc., Enterome, ImmunoGenesis, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
ImmunoCellular Therapeutics Ltd and Genenta Science (Nasdaq: GNTA) are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for ImmunoCellular Therapeutics Ltd, https://bouncewatch.com/company/immunocellular-therapeutics, updated 5 January 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes